ReviewJournal of natural medicines2025
Traditional medicine meets modern science: Halofuginone's role in combating autoimmune diseases.
Review in Journal of natural medicines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Targeting the tumor microenvironment: a new strategy for natural products in breast cancer therapy.Natural products and bioprospecting · 2026Review
- Quinazolinone derivatives as potential anti‑tumor agents: Structural features and molecular mechanisms in inducing cell death (Review).International journal of molecular medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Dichroa febrifuga Lour., a traditional Chinese medicinal herb historically used for malaria treatment, contains the active compound Febrifugine. Through structural modification, Halofuginone was semi-synthesized, retaining antimalarial activity with reduced toxicity. Recent studies reveal Halofuginone's broad biologic activities, including significant therapeutic potential in autoimmune diseases. By modulating abnormal immune responses, suppressing inflammation, and exerting antifibrotic effects, Halofuginone alleviates symptoms and prevents tissue damage in these conditions. This review comprehensively summarizes advances in Halofuginone research for autoimmune diseases and discusses key challenges in this field.
Indexed as
Identifiers
40586966What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.